Lipid-regulating and antiatherosclerotic therapy: Current options and future approaches

Cleveland Clinic Journal of Medicine

Volumn 63, Issue 1, 1996, Pages 31-41

  Gotto Jr , Antonio M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Hypercholesterolemia; Lipid lowering agents; Risk factor reduction

Indexed keywords

ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; COLESTIPOL; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ADULT; CORONARY ARTERY DISEASE; FEMALE; GENE THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; ATHEROSCLEROSIS;

ADULT; ANTILIPEMIC AGENTS; CORONARY DISEASE; FEMALE; GENE THERAPY; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PRACTICE GUIDELINES; RISK FACTORS;

EID: 0029664333     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.63.1.41     Document Type: Article

References (48)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
2. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression. Mew insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87:1781-1791.
3. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289-1298.
4. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolerma. N Engl J Med 1990; 323:946-955.
5. Watts GF, Lewis B, Brunt JNH, et al. Effects of coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339:563-569.
6. Furberg CD, Adams HP Jr, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90:1679-1687.
7. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994; 89:975-990.
8. Pitt B, Ellis SG, Mancini GBJ, Rosman HS, McGovern ME. Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I). Am J Cardiol 1993; 72:31-35.
9. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park J-S, McGovern ME, for the PLAC I Investigators. Pravastatm Limitation of Atherosclerosis in the Coronary Arteries (PLAC I). Reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995; 26:1133-1139.
10. Furberg CD, Byington RP, Crouse JR, Espeland MA. Pravastatin, lipids, and major coronary events. Am J Cardiol 1994; 73:1133-1144.
11. Crouse JR III, Byington RP, Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-11). Am J Cardiol 1995; 75:455-459.
12. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91:2528-2540.
13. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308:367-373.
14. Waters D, Craven TE, Lespétance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 1993; 87:1067-1075.
15. Buchwald H, Matts JP, Fitch LL, et al. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA 1992; 268:1429-1433.
16. Cashin-Hemphill L, Mack W, LaBree L, et al. Coronary progression predicts future cardiac events. Circulation 1993; 88:1-363. Abstract.
17. Falk E. Why do plaques rupture? Circulation 1992; 86(Suppl III):30-42.
18. van Boven AJ, Jukema JW, Paoletti R. Endothelial dysfunction and dyslipidemia: possible effects of lipid lowering and lipid modifying therapy. Pharmacol Res 1994; 29:261-272.
19. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89:2519-2524.
20. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332:480-493.
21. Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyndamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 1994; 89:1530-1538.
22. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reacttve protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331:417-424.
23. Galis ZS, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994; 75:181-189.
24. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89:1329-1445.
25. Ycshurun D, Gotto AM Jr. Hyperlipidemia: perspectives in diagnosis and treatment. South Med J 1995; 88:379-391.
26. Schultz JR, Verstugft JG, Goug EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogemc properties of high density lipoproteins in transgenic mice. Nature 1993; 365:761-764.
27. Austin MA. Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond. Am J Epidemiol 1989; 129:249-259.
28. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991; 11:2-14
29. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographie change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation 1990; 81:470-476.
30. Hodis HN, Mack WJ, Azen SP, et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994; 90:42-49.
31. Bradley WA, Booyse FM, Gianturco SH. Fibrinolytic and thrombotic factors in atherosclerosis and IHD: the influence of triglyceride rich hpoproteins (TGRLP). Atherosclerosis 1994; 108(Suppl):S31-S39.
32. Morrtsett JD, Guyton JR, Gaubatz JW, Gotto AM Jr. Lipoprotem (a): structure, metabolism and epidemiology. In: Gotto AM Jr, editor. Plasma tipoprotems Amsterdam: Elsevier, 1987:129-152.
33. Reaven GM. Role of insulin in human disease (syndrome X): an expanded definition. Annu Rev Med 1993; 44:121-131.
34. Reaven GM, Chen YDI, Jeppesen J, MaKeux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density hpoprotein particles. J Clin Invest 1993; 92:141-146.
35. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment Circulation 1992; 85:37-45.
36. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994; 271:672-677.
37. Black D. Arorvastatin: a step ahead for HMG-CoA reductase inhibitors. Atherosclerosis 1994; 109:88. Abstract.
38. Kirschstein R. From the National Institutes of Health. Largest US clinical trial ever gets under way. JAMA 1993; 270:1521.
39. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial JAMA 1995; 273:199-208.
40. Bergstrom JD, Kurtz MM, Rew DJ, et al. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase Proc Nad Acad Sci USA 1993; 90:80-84.
41. Hidaka Y, Hotta H, Nagata Y, Iwasawa Y, Horie M, Kamei T. Effect of a novel squalene epoxidase inhibitor, NB-598, on the regulation of cholesterol metabolism in Hep D2 cells. J Biol Chem 1991; 266:13171-13177.
42. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330:1029-1035.
43. Walldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994; 74:875-883.
44. Grossman M, Raper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolemia. Nat Genet 1994; 6:335-341.
45. Kozarsky KF, McKinley DR, Austin LL, Raper SE, Stratford-Perricaudet LD, Wilson JM. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyper-lipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994; 269:13695-13702.
46. Kolata G. Gene therapy is approved for cardiovascular study. New York Times 1994 Sept 14;Sect A:8.
47. Simons M, Edelman ER, DeKeyser J-L, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992; 359:67-70.
48. Shi Y, Fard A, Galeo A, et al. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 1994; 90:944-951.